Lenalidomide, bortezomib, and dexamethasone, demonstrate significant clinical efficacy in treating multiple myeloma.

Elevated TNF-α expression in drug- and ICI-AIN correlated with renal response. Infliximab use may offer a therapeutic advantage over steroids alone in stage III or IV ICI-AIN.

P=N/A, N=185, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

Given the patient's immunosuppressed state and atypical presentation, we conclude that bacteremia secondary to folliculitis resulted in occult paraspinal myositis mimicking a muscle strain, and ultimately progressed to septic arthritis. This case highlights the need for high clinical suspicion for hematogenous infection in patients receiving TNF-α inhibitors who present with musculoskeletal pain and minimal systemic findings.

P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025

Our results show that leptin levels are increased (independently of body mass index) in patients with DLBCL belonging to the R2-GDP-GOTEL phase II clinical trial, and these elevated levels are associated with a worse response to treatment and survival using lenalidomide as immunomodulator...Taken together, these data indicate that leptin could be a promising and predictive response biomarker of treatment efficacy in patients with lymphoma. Our findings on leptin in patients with R/R DLBCL could also arouse great interest given its potential applications as a target of treatment.

A cohort of patients diagnosed with psoriasis with blood-dryness pattern were enrolled and randomised into three treatment groups: one receiving secukinumab monotherapy (control group); a matched group receiving tumour necrosis factor (TNF)-α inhibitor (etanercept) plus NBMD therapy (match group), and a third group receiving combination therapy with secukinumab and NBMD therapy (study group). The adjusted hazard ratios were 0.41 (p<0.01) for the study group and 0.45 (p<0.01) for the match group, demonstrating a significantly reduced risk with combination therapy. In this study, combining secukinumab with a modified nourishing and moisturising TCM regimen yielded superior clinical outcomes, including greater symptom relief, improved quality of life, and a reduced risk of superficial fungal infections compared with biologic monotherapy.

Also, mice treated with the TNF-α inhibitor infliximab and fasted for 48 h showed resistance to adiposity loss, suggesting that prolonged fasting-induced TNF signaling may modulate adipose tissue reduction...Interestingly, TNFR1 and IL-18 expressions in sWAT correlate with the expression of lipases and adipokines in the subcutaneous site despite no correlation with body weight or fat mass 1 year after surgery. In summary, this study suggests that the TNF/TNFR1 axis is crucial for metabolic adaptation and is a prerequisite for prolonged fasting-induced lipolysis in male mice.

P2, N=36, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting

P1, N=30, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P=N/A, N=30, Recruiting, University of Pennsylvania | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=38, Completed, Zuyderland Medisch Centrum | Enrolling by invitation --> Completed | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Oct 2025